This application from the Group Health (GH)/University of Washington (UW) eMERGE team proposes specific aims designed to advance integration of genomic data into clinical practice with a focus on clinical discovery and implementation on Mendelian forms of colorectal cancer and/or polyposis (CRC/P) and incidental findings in other actionable genes.
Our aims will also allow us to address challenges involved in bringing genomic medicine into standard medical care. Our focus on CRC/P, and quantitative traits and incidental findings (IF) in other actionable genes represents a unique opportunity to move the field forward towards the goal of bringing genomic medicine into effective, standard medical practice in an everyday community practice setting. We have 3 Aims.
Aim 1 : Genomic medicine discovery and implementation focused on CRC/P, Triglycerides (TG), and neutrophil count (NPC). We proposed sequencing of 1000 CRC and 1000 Asian ancestry participants, to achieve sub- aims of understanding the genetic basis of CRC, TG, and NPC.
Aim 2 : Integrate genomic information into GH-wide clinical care and the EMR. We will develop intuitive, comprehensive reports to return CRC and other genes deemed actionable by the American College of Medical Genetics and Genomics (ACMG). We will incorporate stakeholder input and then to implement integrated processes and tools into an integrated delivery system with a focus on CRC/P and Long QT syndrome. We will develop and evaluate educational outreach and online resources.
Aim 3 : Evaluate the effectiveness and economic impact of result return to patients and their families. We will implement a novel tool to increase family communication of CRC genetic results and evaluate the economic impact and cost effectiveness of this tool as well as of returning IFs. Completion of the work in this eMERGE III proposal will guarantee that the Seattle site remains an engaged and effective leader in the eMERGE network in support of NHGRI's mission to ensure that barriers to successful integration of genomic medicine in clinical care are overcome.
This eMERGE III proposal builds on past discoveries and research designed to translate genomic advances into clinical care involving clinicians, patients and families. This phase focuses on traits associated with preventable health concerns: colon cancer, triglycerides, and immunity. We address optimal methods to share information across families and whether other information found by genomic tests impact the care, health, and medical costs of individuals.
|Kauffman, Tia L; Wilfond, Benjamin S; Jarvik, Gail P et al. (2017) Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing. Contemp Clin Trials 53:100-105|
|Patel, Ronak Y; Shah, Neethu; Jackson, Andrew R et al. (2017) ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variants. Genome Med 9:3|
|Sanderson, Saskia C; Brothers, Kyle B; Mercaldo, Nathaniel D et al. (2017) Public Attitudes toward Consent and Data Sharing in Biobank Research: A Large Multi-site Experimental Survey in the US. Am J Hum Genet 100:414-427|
|Jones, Gregory T; Tromp, Gerard; Kuivaniemi, Helena et al. (2017) Meta-Analysis of Genome-Wide Association Studies for Abdominal Aortic Aneurysm Identifies Four New Disease-Specific Risk Loci. Circ Res 120:341-353|
|Leppig, Kathleen A; Thiese, Heidi A; Carrel, David et al. (2017) Building a family network from genetic testing. Mol Genet Genomic Med 5:122-129|
|Laurino, Mercy Y; Truitt, Anjali R; Tenney, Lederle et al. (2017) Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry. Mol Genet Genomic Med 5:700-708|
|Dumitrescu, Logan; Ritchie, Marylyn D; Denny, Joshua C et al. (2017) Genome-wide study of resistant hypertension identified from electronic health records. PLoS One 12:e0171745|
|Himes, Patricia; Kauffman, Tia L; Muessig, Kristin R et al. (2017) Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing. Genet Med 19:803-808|
|Goodman, Jessie L; Amendola, Laura M; Horike-Pyne, Martha et al. (2017) Discordance in selected designee for return of genomic findings in the event of participant death and estate executor. Mol Genet Genomic Med 5:172-176|
|Kirby, Jacqueline C; Speltz, Peter; Rasmussen, Luke V et al. (2016) PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc 23:1046-1052|
Showing the most recent 10 out of 42 publications